Engineered acid and heat stable proteins through directed evolution
Aureka Biotechnologies applies AI-powered directed evolution to engineer proteins with enhanced acid and heat stability. Using high-throughput microfluidics, synthetic biology, and single-cell functional screening, the platform accelerates protein therapeutic discovery and enables rational protein engineering for demanding applications.
Overview
Aureka Biotechnologies offers an AI-powered, integrated digital biology platform that engineers proteins with improved acid and heat stability through directed evolution. The platform combines high-throughput microfluidics, synthetic biology, and geometric protein language models to execute rapid generate-test-learn-optimize cycles at scale. By generating large-scale, multi-metric data on protein candidates through single-cell functional screening, Aureka transforms protein engineering from empirical trial-and-error into a rational, design-driven practice.
This capability is particularly valuable for developing protein therapeutics that must withstand harsh manufacturing, storage, and physiological conditions, as well as for industrial enzymes and other proteins deployed in challenging environments.
Technical specifications
Key capabilities:
- Directed evolution platform that engineers proteins for enhanced stability under acidic and elevated-temperature conditions
- AI-driven design powered by geometric protein language models that predict and prioritize high-value protein variants
- High-throughput screening using microfluidic single-cell functional assays to capture multi-metric performance data
- Synthetic biology workflows that enable rapid generation and testing of protein variant libraries
- Generate-test-learn-optimize cycles that accelerate convergence toward improved protein candidates
- Multi-metric data generation supporting rational decision-making across stability, function, and developability attributes
Applications:
- Protein therapeutics requiring improved formulation stability and shelf life
- Antibody and biologic candidates targeting inflammatory and cardiometabolic diseases
- Receptor agonists and epitope-specific targets that are difficult to access through conventional discovery
- Industrial enzymes and proteins requiring resilience to acidic or high-temperature processing conditions
Technology readiness level
Aureka is actively applying its directed evolution platform to build an internal pipeline of differentiated therapeutic candidates for inflammatory and cardiometabolic diseases, while engaging in strategic partnerships to address complex targets such as receptor agonists and epitope-specific proteins. The platform is positioned to reduce cost and timelines in pharmaceutical discovery by replacing empirical screening with engineered, data-driven protein design. Specific validation procedures, hypothesis details, and future validation plans are available directly from Dr. Weian Zhao at Aureka Biotechnologies.
About Aureka Biotechnologies
Aureka Biotechnologies is a tech-bio startup that provides an AI-powered, integrated digital biology platform designed to accelerate the discovery of protein therapeutics. The company utilizes high-throughput technologies, including microfluidics and synthetic biology, to perform rapid generate-test-learn-optimize cycles. By generating large-scale, multi-metric data on therapeutic candidates through single-cell functional screening and geometric protein language models, Aureka aims to transition drug development from empirical trial-and-error methods to a rational, engineering-focused practice.
This platform enables the identification of high-value antibody therapeutics that are otherwise difficult to access via conventional discovery methods. Aureka is applying these capabilities to develop an internal pipeline of differentiated candidates targeting inflammatory and cardiometabolic diseases, while also engaging in strategic partnerships to address complex therapeutic challenges such as receptor agonists and epitope-specific targets. The technology is intended to increase efficiency and reduce costs in the pharmaceutical discovery process, offering potential solutions for difficult drug targets and mechanisms.
delivered to your inbox.